biotechnology company
Company profile
Ticker
HUMA, HUMAW
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Alpha Healthcare Acquisition Corp.
SEC CIK
Corporate docs
IRS number
851763759
HUMA stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
22 Mar 24
8-K
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
4 Mar 24
424B5
Prospectus supplement for primary offering
1 Mar 24
424B5
Prospectus supplement for primary offering
29 Feb 24
8-K
Other Events
29 Feb 24
8-K
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
9 Feb 24
8-K
Other Events
12 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
Transcripts
HUMA
Earnings call transcript
2023 Q4
22 Mar 24
HUMA
Earnings call transcript
2023 Q3
9 Nov 23
HUMA
Earnings call transcript
2023 Q2
14 Aug 23
HUMA
Earnings call transcript
2023 Q1
12 May 23
HUMA
Earnings call transcript
2022 Q4
24 Mar 23
HUMA
Earnings call transcript
2022 Q3
10 Nov 22
HUMA
Earnings call transcript
2022 Q2
12 Aug 22
HUMA
Earnings call transcript
2022 Q1
13 May 22
HUMA
Earnings call transcript
2021 Q4
29 Mar 22
Latest ownership filings
SC 13D/A
Niklason Laura E
8 Mar 24
SC 13D/A
FRESENIUS MEDICAL CARE HOLDINGS INC /NY/
7 Mar 24
4
William John Scheessele
12 Dec 23
4
Heather Ledbetter Prichard
12 Dec 23
4
Shamik J Parikh
12 Dec 23
4
Yang Cao
12 Dec 23
4
Dale A. Sander
12 Dec 23
4
Brady W Dougan
12 Dec 23
4
Laura E Niklason
12 Dec 23
SC 13D/A
FRESENIUS MEDICAL CARE HOLDINGS INC /NY/
1 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 100.34 mm | 100.34 mm | 100.34 mm | 100.34 mm | 100.34 mm | 100.34 mm |
Cash burn (monthly) | 4.75 mm | 5.28 mm | 8.21 mm | 7.89 mm | 4.34 mm | 6.10 mm |
Cash used (since last report) | 31.49 mm | 34.98 mm | 54.35 mm | 52.24 mm | 28.71 mm | 40.40 mm |
Cash remaining | 68.85 mm | 65.36 mm | 45.99 mm | 48.10 mm | 71.63 mm | 59.94 mm |
Runway (months of cash) | 14.5 | 12.4 | 5.6 | 6.1 | 16.5 | 9.8 |
Institutional ownership, Q3 2023
26.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 85 |
Opened positions | 16 |
Closed positions | 7 |
Increased positions | 38 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 48.42 bn |
Total shares | 31.74 mm |
Total puts | 95.80 k |
Total calls | 1.50 k |
Total put/call ratio | 63.9 |
Largest owners | Shares | Value |
---|---|---|
PTC Trustees GY Ltd as Trustee of The GYF Trust | 8.94 mm | $0.00 |
Laura E Niklason | 6.19 mm | $21.92 mm |
BLK Blackrock | 4.50 mm | $13.19 bn |
Vanguard | 3.02 mm | $8.85 bn |
Geode Capital Management | 1.23 mm | $3.60 bn |
Millennium Management | 1.23 mm | $3.59 bn |
STT State Street | 1.13 mm | $3.30 bn |
Prescott General Partners | 568.25 k | $1.66 bn |
NTRS Northern Trust | 518.59 k | $1.52 bn |
Charles Schwab Investment Management | 458.46 k | $1.34 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Dec 23 | Brady W Dougan | Stock Options Common Stock | Grant | Acquire A | Yes | No | 10.28 | 525 | 5.40 k | 2,100 |
11 Dec 23 | Heather Ledbetter Prichard | Stock Options Common Stock | Grant | Acquire A | No | No | 10.28 | 525 | 5.40 k | 2,100 |
11 Dec 23 | Dale A. Sander | Stock Options Common Stock | Grant | Acquire A | No | No | 10.28 | 525 | 5.40 k | 2,100 |
8 Dec 23 | Brady W Dougan | Stock Options Common Stock | Grant | Acquire A | Yes | No | 2.8 | 803,000 | 2.25 mm | 803,000 |
8 Dec 23 | Yang Cao | Stock Options Common Stock | Grant | Acquire A | No | No | 2.8 | 210,000 | 588.00 k | 210,000 |
8 Dec 23 | Heather Ledbetter Prichard | Stock Options Common Stock | Grant | Acquire A | No | No | 2.8 | 290,000 | 812.00 k | 290,000 |
8 Dec 23 | Shamik J Parikh | Stock Options Common Stock | Grant | Acquire A | No | No | 2.8 | 283,000 | 792.40 k | 283,000 |
8 Dec 23 | Dale A. Sander | Stock Options Common Stock | Grant | Acquire A | No | No | 2.8 | 301,000 | 842.80 k | 301,000 |
News
Tommy Tuberville Trades Raise Eyebrows Again: Senator Sells Put Options, Buys Small Biotech Linked To Ukraine-Russia War
17 Apr 24
Piper Sandler Maintains Neutral on Humacyte, Maintains $4 Price Target
26 Mar 24
Benchmark Reiterates Buy on Humacyte, Maintains $15 Price Target
25 Mar 24
Earnings Scheduled For March 22, 2024
22 Mar 24
Investor Optimism Improves Slightly; Dow Jumps Over 250 Points
22 Mar 24
Press releases
Humacyte to Host Virtual KOL Event "Hemodialysis Access: A Crossroads of Care," on March 28, 2024
26 Mar 24
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
22 Mar 24
Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference
1 Mar 24
Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock
29 Feb 24
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
29 Feb 24